Skip to main
IMRNW
IMRNW logo

Immuron Ltd Warrant 2017-12.05.22 on Immuron Sp ADR (IMRNW)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy IMRNW Stock

About Immuron Ltd Warrant 2017-12.05.22 on Immuron Sp ADR (IMRNW)

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Deve...read more
Market cap
Today's volume
Revenue (TTM)
Avg. daily volume
EBITDA (TTM)
Open
Price / earnings ratio
Today's range
Debt / equity
52 week range
5 year debt / equity
Beta (LTM)
Interest coverage
Dividend & yield— (—)
Current ratio
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy IMRNW stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in IMRNW stock

    Navigate to the Explore page. Then, type IMRNW into the search bar. When you see IMRNW stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased IMRNW stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy IMRNW Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.